关键词: 分化型甲状腺癌, 术后管理, 促甲状腺激素, 促甲状腺激素抑制治疗

Abstract: Current status and thinking of postoperative thyroid stimulating hormone suppression therapy for differentiated thyroid cancer        CHENG Ruo- chuan. Department of Thyroid Surgery, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
Abstract    The low rate of reaching the treatment target is the main problem faced by thyroid stimulating hormone (TSH) inhibition therapy at present. Evidence-based medical evidence shows that TSH inhibition therapy can reduce the risk of tumor recurrence and prolong survival time in patients with differentiated thyroid cancer. Reviewing the evolution of the guidelines, from the introduction and refinement of the concept of initial recurrence risk stratification, the relaxation of TSH control objectives for those at low risk of recurrence, to the establishment of a dual risk assessment system for dynamic efficacy and side effects, it can be seen that TSH inhibition treatment and monitoring are moving towards personalized, accurate, and dynamic evaluation, from meeting standards and actively preventing and treating side effects. How strengthen regular and effective follow-up for patients urgently requires the attending physician to actively participate in the development and implementation of a modern intelligent follow-up model.

Key words: differentiated thyroid cancer, postoperative management, thyroid-stimulating hormone（TSH）, TSH suppression therapy